T Y Jeon1, C K Kim1,2, J-H Kim1, G H Im3, B K Park1, J H Lee3. 1. 1 Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 2. 2 Department of Medical Device Management and Research, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea. 3. 3 Department of Radiology and Center for Molecular and Cellular Imaging, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Abstract
OBJECTIVE: To investigate the feasibility of dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted MRI (DWI) in monitoring early therapeutic response to sorafenib in renal cell carcinoma (RCC) xenograft models. METHODS: Sorafenib (40 mg kg(-1)) was administered orally to BALB/c nude mice (n = 9) bearing subcutaneous tumours of human RCC ACHN xenografts. DCE-MRI and DWI were obtained 0, 1, 3 and 7 days after therapy, and DCE-MRI parameters (K(trans) and ve) and apparent diffusion coefficient (ADC) values were calculated. Tumour size and volume changes were correlated with changes in DCE-MRI parameters or ADC values after therapy. RESULTS: Following therapy, K(trans) showed a significant decrease over time (p = 0.005), whereas ve did not demonstrate significant changes between time points (p = 0.97). ADC values showed a progressive increase over time (p = 0.004). Compared with pre-therapy, K(trans) showed a significant decrease after 3 days of therapy (p = 0.039), and ADC values increased significantly after 7 days (p = 0.039). Tumour size and volume did not show significant changes during 7 days. Tumour size and volume changes were not associated with changes in DCE-MRI parameters or ADC values. CONCLUSION: DCE-MRI and DWI may show early physiological changes within 1 week after initiating sorafenib treatment on human RCC xenografts. ADVANCES IN KNOWLEDGE: The quantitative parameters of DCE-MRI and DWI may offer the potential for assessing early therapeutic response to sorafenib in clinical trials.
OBJECTIVE: To investigate the feasibility of dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted MRI (DWI) in monitoring early therapeutic response to sorafenib in renal cell carcinoma (RCC) xenograft models. METHODS:Sorafenib (40 mg kg(-1)) was administered orally to BALB/c nude mice (n = 9) bearing subcutaneous tumours of humanRCC ACHN xenografts. DCE-MRI and DWI were obtained 0, 1, 3 and 7 days after therapy, and DCE-MRI parameters (K(trans) and ve) and apparent diffusion coefficient (ADC) values were calculated. Tumour size and volume changes were correlated with changes in DCE-MRI parameters or ADC values after therapy. RESULTS: Following therapy, K(trans) showed a significant decrease over time (p = 0.005), whereas ve did not demonstrate significant changes between time points (p = 0.97). ADC values showed a progressive increase over time (p = 0.004). Compared with pre-therapy, K(trans) showed a significant decrease after 3 days of therapy (p = 0.039), and ADC values increased significantly after 7 days (p = 0.039). Tumour size and volume did not show significant changes during 7 days. Tumour size and volume changes were not associated with changes in DCE-MRI parameters or ADC values. CONCLUSION:DCE-MRI and DWI may show early physiological changes within 1 week after initiating sorafenib treatment on humanRCC xenografts. ADVANCES IN KNOWLEDGE: The quantitative parameters of DCE-MRI and DWI may offer the potential for assessing early therapeutic response to sorafenib in clinical trials.
Authors: M Pedersen; J Mørkenborg; F T Jensen; H Stødkilde-Jørgensen; J C Djurhuus; J Frokiaer Journal: J Magn Reson Imaging Date: 2000-08 Impact factor: 4.813
Authors: Martin D Pickles; Martin Lowry; David J Manton; Peter Gibbs; Lindsay W Turnbull Journal: Breast Cancer Res Treat Date: 2005-05 Impact factor: 4.872
Authors: P Schöffski; H Dumez; P Clement; A Hoeben; H Prenen; P Wolter; S Joniau; T Roskams; H Van Poppel Journal: Ann Oncol Date: 2006-01-17 Impact factor: 32.976
Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: A R Padhani; A D MacVicar; C J Gapinski; D P Dearnaley; G J Parker; J Suckling; M O Leach; J E Husband Journal: Radiology Date: 2001-02 Impact factor: 11.105
Authors: Siver A Moestue; Else M Huuse; Evita M Lindholm; Anna Bofin; Olav Engebraaten; Gunhild M Mælandsmo; Lars A Akslen; Ingrid S Gribbestad Journal: J Magn Reson Imaging Date: 2013-03-21 Impact factor: 4.813
Authors: Yulian Mytsyk; Serhiy Pasichnyk; Ihor Dutka; Ihor Dats; Dmytro Vorobets; Michał Skrzypczyk; Yerzhan Uteuliyev; Andrea Botikova; Katarina Gazdikova; Peter Kubatka; Peter Urdzik; Peter Kruzliak Journal: Clin Exp Med Date: 2020-02-05 Impact factor: 3.984
Authors: Johannes Linxweiler; Christina Körbel; Andreas Müller; Eva Jüngel; Roman Blaheta; Joana Heinzelmann; Michael Stöckle; Kerstin Junker; Michael D Menger; Matthias Saar Journal: Sci Rep Date: 2017-10-27 Impact factor: 4.379